PURE Bioscience Appoints Sixth New Board Member
2013年10月8日 - 9:30PM
Marketwired
PURE Bioscience Appoints Sixth New Board Member
Experienced Business Executive From Food Manufacturing
SAN DIEGO, CA--(Marketwired - Oct 8, 2013) - PURE
Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen
citrate (SDC) antimicrobial, today announced the appointment of
William Otis to its Board of Directors. Mr. Otis is the sixth
member to join the Company's Board of Directors.
Mr. Otis is currently the President and Chief Operating Officer
of Patrick Cudahy, LLC and Saratoga Food Specialties. Both
companies are food manufacturing companies of John Morrell Food
Group and Smithfield Foods. Mr. Otis began his career in 1980
with Oscar Mayer Foods Corporation serving in several operations,
finance and marketing positions. In 1995, Mr. Otis joined
Patrick Cudahy, serving as Vice President of Sales and Marketing
and in 2004 was promoted to President and COO. Mr. Otis also took
over the President and COO role at Saratoga Food Specialties in
2012. Mr. Otis earned his Master's Degree in Business
Management from the University of Wisconsin-Madison.
"Food-borne illness is an ever-increasing problem that needs
new, safe and effective solutions along the various stages from
farm to table," stated Bill Otis, "I believe PURE's SDC-based
products represents an innovative and exciting opportunity to
provide a broad-spectrum antimicrobial solution to pathogen control
in the food industry."
"We believe the addition of Bill Otis to our board elevates the
credibility of our SDC technology as a new antimicrobial paradigm
in the food industry," stated Dave Pfanzelter, Chairman of the
Board of Directors of PURE. "It is our belief that Bill provides
not only the operational experience in mitigation strategies
against food contamination, but also the strategic insight in
developing and building a sustainable business."
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based
bioscience products that provide solutions to numerous global
health challenges, including Staph (MRSA) and Carbapenem-resistant
Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high
efficacy/low toxicity bioscience technologies, including its silver
dihydrogen citrate-based antimicrobials, represent innovative
advances in diverse markets and lead today's global trend toward
industry and consumer use of "green" products while providing
competitive advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
Forward-looking Statements
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "expect," "intend," "project" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed business initiatives and plans, acceptance of the
Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new
products and receive regulatory approvals of such products,
competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
Contact: Investor Relations Tom Hemingway, Redwood Investment
Group 714.927.9118 Peter C.
Wulff, CFO & COO Pure Bioscience, Inc. 619.596.8600
ext.111
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 8 2024 まで 9 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 9 2023 まで 9 2024